Kucera Pharmaceutical Co. announced that the company is working on a new chemical molecule, called KPC-2, that has shown promise in preventing HIV replication, the Winston-Salem [N.C.] Journal reports. The man-made molecule can be injected or taken orally, and early tests have shown that it is safe for human use. A commercial lab is currently testing the molecule to determine if it is as effective when administered orally as opposed to being injected, how the body processes the molecule, and its long-term effects. Researchers also are continuing to study precisely how KPC-2 prevents HIV from copying itself. Kucera CEO Russ Read said, "We're not sure how it works, but it's a new mode toward treating HIV." The company plans to seek Food and Drug Administration approval of KPC-2 as an investigational new drug in order to begin clinical trials.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














